These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 16865244)
1. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU. Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244 [TBL] [Abstract][Full Text] [Related]
2. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors. Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056 [TBL] [Abstract][Full Text] [Related]
3. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Itashiki Y; Harada K; Ferdous T; Yoshida H Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527 [TBL] [Abstract][Full Text] [Related]
4. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts. Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536 [TBL] [Abstract][Full Text] [Related]
5. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373 [TBL] [Abstract][Full Text] [Related]
6. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Harada K; Kawaguchi S; Supriatno ; Onoue T; Yoshida H; Sato M Oral Oncol; 2004 Aug; 40(7):713-9. PubMed ID: 15172641 [TBL] [Abstract][Full Text] [Related]
7. [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. Fukushima M Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968 [TBL] [Abstract][Full Text] [Related]
8. Chemo-radio-gene therapy for colorectal cancer cells using Escherichia coli uracil phosphoribosyltransferase gene. Koyama F; Fujii H; Mukogawa T; Ueno M; Hamada H; Ishikawa H; Doi S; Nakao T; Matsumoto H; Shimatani H; Takeuchi T; Nakajima Y Anticancer Res; 2003; 23(2B):1343-8. PubMed ID: 12820392 [TBL] [Abstract][Full Text] [Related]
9. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil. Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960 [TBL] [Abstract][Full Text] [Related]
10. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858 [TBL] [Abstract][Full Text] [Related]
11. Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts. Nakagawa T; Otsuki N; Masai Y; Sasaki R; Tsukuda M; Nibu K Acta Otolaryngol; 2008 Aug; 128(8):936-40. PubMed ID: 18607998 [TBL] [Abstract][Full Text] [Related]
12. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. Ojima E; Inoue Y; Watanabe H; Hiro J; Toiyama Y; Miki C; Kusunoki M Oncol Rep; 2006 Nov; 16(5):1085-91. PubMed ID: 17016597 [TBL] [Abstract][Full Text] [Related]
13. Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma. Harada K; Ferdous T; Yoshida H Oncol Rep; 2007 Nov; 18(5):1077-83. PubMed ID: 17914556 [TBL] [Abstract][Full Text] [Related]
14. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor. Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo. Nukatsuka M; Saito H; Sakamoto K; Nakagawa F; Uchida J; Kobunai T; Shiraishi K; Takechi T Anticancer Res; 2012 Jul; 32(7):2807-12. PubMed ID: 22753741 [TBL] [Abstract][Full Text] [Related]
16. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174 [TBL] [Abstract][Full Text] [Related]
17. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Stackhouse MA; Pederson LC; Grizzle WE; Curiel DT; Gebert J; Haack K; Vickers SM; Mayo MS; Buchsbaum DJ Gene Ther; 2000 Jun; 7(12):1019-26. PubMed ID: 10871750 [TBL] [Abstract][Full Text] [Related]
18. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Kunnumakkara AB; Diagaradjane P; Guha S; Deorukhkar A; Shentu S; Aggarwal BB; Krishnan S Clin Cancer Res; 2008 Apr; 14(7):2128-36. PubMed ID: 18381954 [TBL] [Abstract][Full Text] [Related]
19. Preclinical analysis of the antitumor efficacy of TS-1 using human uterine cervical cancer tumor xenografts. Nagai N; Komatsu M; Yunokawa M; Shiroyama Y; Hirata E Oncol Rep; 2008 Nov; 20(5):1149-56. PubMed ID: 18949415 [TBL] [Abstract][Full Text] [Related]
20. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil]. Shirasaka T; Shimamoto Y; Kato T; Fukushima M Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]